The General Office of the Guangzhou Municipal People's Government has issued the "Guangzhou City Plan for Accelerating the Construction of a Strong Advanced Manufacturing City (2024-2035)." The plan emphasizes accelerating the strategic layout of innovative drugs and vigorously developing biopharmaceuticals such as monoclonal antibodies, vaccines, blood products, and diagnostic reagents.

It calls for forward-looking deployment around major life and health issues and cutting-edge biotechnologies, striving for breakthroughs in genetic engineering technologies, novel drug targets and mechanisms of action, and the integration of synthetic biology with bioinformatics. Leveraging the distinctive advantages of Lingnan traditional Chinese medicine, the plan aims to accelerate the standardization and internationalization of Chinese medicine, creating a number of exemplary industrial chains spanning from active pharmaceutical ingredients and medicinal herbs to finished drugs.

By 2035, the goal is to establish Guangzhou as a nationally leading hub for the biopharmaceutical and high-end medical device industries. The foundational R&D capabilities of the industry will be further strengthened, the industrial chain will become more robust, and the industrial scale is projected to reach the 500 billion yuan level.